Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

What doses would you treat the primary and lymph nodes in node positive vulvar cancer patient with incidentally found focal SCC in a field of VIN3?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

I would treat the primary and inguinal nodes if no additional surgery and SNLN planned. Dose to primary is a function of microscopic or macroscopic disease left behind: 54-56 Gy if microscopic but 60 or above if macroscopic.

What dose constraints would you use for head and neck SBRT in a previously untreated field?

4
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Ohio State University

The use of SBRT as a primary modality in patients who have not undergone previous irradiation and are not felt to be candidates for surgery or definitive chemoradiation varies institutionally, with some preferring to treat with hypofractionated regimens (particularly when they are candidates for che...

Would you offer PMRT for cT2N0 triple negative breast cancer s/p NAC and mastectomy with residual disease and no positive lymph nodes?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

We need more data. For microscopic residual have not been offering it but if there is residual disease more than 2 cm, we would consider the patient for PMRT.

For cT2N0 bladder cancer receiving definitive chemoRT, do you cover the prostate if you are not treating pelvic nodes?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Washington University School of Medicine

I generally include the prostatic urethra but I don’t intentionally treat the entire prostate gland. The exception would be a patient who has a concurrent clinically significant cancer which is not very common. By avoiding the posterior prostate you minimize the volume of the rectum that will be inc...

How would you manage a patient with primary CNS lymphoma who is not a candidate for high-dose methotrexate?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Washington University School of Medicine

This is a relatively rare situation in my experience, but I think WBRT is the second most active agent for PCNSL after high-dose MTX, so if MTX is not possible, I would strongly consider WBRT. Hypothetically, if patient has good PS and you are going for "curative intent", the standard WBRT alone app...

What is your IGRT strategy for prone breast radiation?

2
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

We have been using KV/Mv imaging matching both to chest wall and breast tissue like supine position

How do you manage classical early stage Hodgkin lymphoma patients when an ESR is not checked as part of their workup?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Washington University School of Medicine

I personally don't think ESR plays a huge factor in the management of early stage Hodgkin Lymphoma now in the era of PET-adapted treatment selection. So, if a patient has very favorable stage I-IIA HL meeting all other criteria by the GHSH study and is interested to not have combined modality treatm...

For gross supraclavicular disease in lung cancer, do you cover full dose to the involved lymph node with margin or to the entire supraclavicular fossa?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · UCF COM

Sometimes the supraclav area has smaller nodes, that are difficult to palpate. As such, I treat the entire sc fossa...cost is little and recurrence is very difficult to treat. Dose fall off with a margin on a single palpable node may cause a local failure.

When using EBRT to deliver APBI, what dose do you prescribe and to what volume?

2
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Allegheny Health Network, Pittsburgh

3DCRT APBI now has greater data supporting potential toxicity based on results of institutional series, prospective (RTOG), and now randomized data (late toxicity with RAPID). Whether this is related to technique, volumes, or fractionation (3.85 BID) is unclear.For patients at our institution, we us...

What dose and fractionation do you use for definitive radiation for SCC in situ of glottic larynx?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Florida

63 Gy/28 fractions larynx only; 93% local control